You are here

Article Text

Article menu
Download PDFPDF
DTB select
Tirzepatide for weight reduction in people without diabetes

https://doi.org/10.1136/dtb.2025.000018

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key learning points

    • A 72-week placebo-controlled trial evaluated the effect of once weekly injections of tirzepatide in people with a body mass index of at least 27 kg/m2 who did not have diabetes.

    • Participants also received lifestyle counselling sessions to support 150 min of physical activity/week and a dietary deficit of 500 cals/day.

    • At 72 weeks, the difference from placebo in mean weight change was −11.9%, −16.4% and −17.8% in the 5 mg, 10 mg and 15 mg tirzepatide dose groups, respectively.

    In the SURMOUNT-1 trial, a once weekly injection of tirzepatide plus lifestyle intervention provided substantial weight loss over 72 weeks compared with placebo plus lifestyle intervention.1

    Overview

    The SURMOUNT-1 trial was a phase 3 multicentre double-blind randomised placebo-controlled trial conducted at 118 sites in Argentina, Brazil, China, India, Japan, Mexico, Russia, Taiwan and the USA between December 2019 and April 2022.1 2 The trial recruited adults aged …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.